Skip to content

A clinical trial to see the effect of Tranexamic Acid in reducing blood loss during cesarean section

Role of prophylactic Tranexamic Acid in reducing blood loss during Cesarean Section: a double blind Placebo Control Randomised Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/02/031579
Enrollment
72
Registered
2021-02-26
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O00-O9A- Pregnancy, childbirth and the puerperium

Interventions

Intervention1: Tranexamic Acid (TXA): TXA injection will be prepared by diluting 1 gram (10ml) TXA in 100ml of NS. TXA will be administered as intravenous infusion (over 15 minutes), at least 20 minut

Sponsors

AIIMS Raipur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects with singleton pregnancy (parity not more than 3) 2. Age � 18 and 3. � 37 weeks and 4. Alive fetus. 5. Hb � 9 g % in recent 3rd trimester report. 6. Subjects receiving spinal anaesthesia for Cesarean Section

Exclusion criteria

Exclusion criteria: 1. History of venous (deep vein thrombosis and/or pulmonary embolism) or arterial (angina pectoris, myocardial infarction, stroke) thrombosis 2. Subjects with medical disorders like chronic hypertension, renal disease, heart disease, liver disease complicating pregnancy 3. Known case of coagulation disorders 4. Pregnancy related complication like severe preeclampsia, multiple pregnancy, polyhydramnios, and macrosomia, with abnormal placentation, previous two or more caesarean sections 5. Intrauterine death 6. Woman on anticoagulant therapy during the week before delivery 7. Sickle cell disease 8. History of seizures 9. Allergy to TXA.

Design outcomes

Primary

MeasureTime frame
� The intraoperative and postoperative volume of blood loss in the study group (those who received preoperative Tranexamic Acid) and placebo group (those who did not receive Tranexamic Acid)Timepoint: � The intraoperative blood loss from time of placenta delivery to vaginal toileting. Postoperative blood loss is from end of vaginal toileting to 3 hours postpartum

Secondary

MeasureTime frame
� Mean change in hemoglobin between before surgery and 48 hours post surgery in both the groups. � Proportion of women requiring supplementary uterotonic agent other other than routine use of inj. oxytocin 10 mg intramuscular injection immediately after delivery of the baby. Timepoint: Intraoperative period will be considered from skin incision to completion of vaginal toileting. Postoperative period will be considered from from completion of vaginal toileting to first 3 hours.

Countries

India

Contacts

Public ContactNutan Sinha

All India Institute of Medical Sciences, Raipur

dr.sarita.rajbhar@gmail.com7903977598

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 6, 2026